Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-25-014805
Filing Date
2025-03-26
Accepted
2025-03-25 18:16:46
Documents
122
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K xfor-20241231.htm   iXBRL 10-K 2112410
2 EX-10.35 ex1035amendmentno3toaptuit.htm EX-10.35 14760
3 EX-10.38 ex1038norgine.htm EX-10.38 553648
4 EX-23.1 ex-231x4x10xkpwcconsentxfy.htm EX-23.1 2405
5 EX-31.1 ex-311q42024.htm EX-31.1 9254
6 EX-31.2 ex-312q42024.htm EX-31.2 9242
7 EX-32.1 ex-321q42024.htm EX-32.1 5447
  Complete submission text file 0001628280-25-014805.txt   11875709

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20241231.xsd EX-101.SCH 90186
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20241231_cal.xml EX-101.CAL 92679
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20241231_def.xml EX-101.DEF 373491
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20241231_lab.xml EX-101.LAB 936186
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20241231_pre.xml EX-101.PRE 698038
125 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20241231_htm.xml XML 1572121
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38295 | Film No.: 25769602
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)